Rafael Holdings (Rafael Holdings) Interest Expense : $0.00 Mil (TTM As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Rafael Holdings's interest expense for the three months ended in Jan. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jan. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Rafael Holdings's Operating Income for the three months ended in Jan. 2024 was $ -3.14 Mil. Rafael Holdings's Interest Expense for the three months ended in Jan. 2024 was $ 0.00 Mil. Rafael Holdings has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Rafael Holdings Interest Expense Historical Data

The historical data trend for Rafael Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rafael Holdings Interest Expense Chart

Rafael Holdings Annual Data

Trend

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Interest Expense

Get a 7-Day Free Trial

-0.66

-0.08

-0.01

Rafael Holdings Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Rafael Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rafael Holdings (NYSE:RFL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rafael Holdings's Interest Expense for the three months ended in Jan. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Jan. 2024 was $-3.14 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jan. 2024 was $0.00 Mil.

Rafael Holdings's Interest Coverage for the quarter that ended in Jan. 2024 is calculated as

Rafael Holdings had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Rafael Holdings Inc has enough cash to cover all of its debt. Its financial situation is stable.

Rafael Holdings (Rafael Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

520 Broad Street, Newark, NJ, USA, 07102

Website

https://www.rafaelholdings.com

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Executives

I9 Plus, Llc	10 percent owner	153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas	director
Mary Margaret Huizinga	officer: Chief Devel. & Medical Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin	officer: Chief Legal Officer	C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik	officer: CHIEF EXECUTIVE OFFICER	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling	officer: Chief Commercial Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky	officer: Chief Financial Officer	90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash	director, officer: President	C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102